Headquartered in Emeryville, CA Fiscal year ends December NASDAQ: BIOA bioagelabs.com
BioAge Labs is a clinical-stage biopharmaceutical company developing therapies for cardiometabolic diseases by targeting the biology of human aging. It has no commercial products; its revenue comes from research collaborations, including a multi-year target-discovery collaboration with Novartis and an antibody collaboration with Lilly ExploR&D.
Its lead candidate, BGE-102, is an oral, once-daily, brain-penetrant small-molecule NLRP3 inhibitor for inflammation-driven diseases. BGE-102 completed a Phase 1 SAD/MAD trial showing up to 98% IL-1β suppression and median hsCRP reductions of 86%. It is now in two Phase 2 trials:
- QUELL-CV, in adults with obesity and elevated inflammation (cardiovascular risk), with data expected in Q4 2026.
- QUELL-DME, in diabetic macular edema, with data expected in the second half of 2027.
The company is also developing long-acting injectable and oral APJ (apelin receptor) agonists as an exercise-mimetic approach to obesity, targeting an IND by year-end 2026. Additional preclinical programs draw on a proprietary discovery platform built on human longevity data, supplemented by an AI-driven discovery collaboration with Deep Origin. Updated
Pre-Market Stock Futures: Futures are trading mixed on Wednesday, after a rough day for technology stocks and the Nasdaq. The combination of the prospect of a longer struggle with Iran, and higher…
BioAge Labs is a clinical-stage biopharmaceutical company developing therapies for cardiometabolic diseases by targeting the biology of human aging.
The Wall Street consensus 12-month price target for BIOA is $28.89.
